Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

People attending a football match will be asked to sign up to a stem cell register in the hope of finding a donor for a local ...

T-Mobile is the third-largest wireless carrier in the United States, with its popularity largely down to its network coverage and the wide range of tempting offers available. They span from T ...

The microenvironment of Hodgkin's lymphoma is affected by IL-5 which recruits eosinophiles and by TARC/CCL17 which attract CD4+ T-lymphocytes. CCR4, the receptor for TARC, is a target for therapy of ...

However, leukemia originates in the bone marrow and spreads through the blood, while lymphoma originates in the spleen or lymph nodes and spreads through the lymph vessels. Leukemia and lymphoma can ...

PF-08046045 is under clinical development by Pfizer and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase ...